Neogenomics Revenues Grow 49 Percent, Sees Profit in Q2 | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer genetics testing company Neogenomics said on Thursday that revenues during the second quarter rose 49 percent year over year as test volume increased 57 percent.

For the period ended June 30, revenues totaled $15.6 million, up from $10.5 million a year ago as the number of tests performed jumped to 28,846 from 18,358.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.